Pan Solid Tumors

Cancer Type

Whole Blood

Sample Type

7~10 Working Days

Turnaround Time ¹

ACTLiquid™ Pro is a comprehensive NGS-based liquid biopsy assay for pan-solid tumors covering 523 genes and 23 fusion gene variants in circulating tumor DNA. Treatment evaluations include targeted therapy, immunotherapy, and hormone therapy.

Precision Medicine to Plan Better Treatment

Precision Medicine to Plan Better Treatment

Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling can identify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.

Learn More

Why ACT Genomics?

Humane Process

Avoids multiple biopsies and the time cost associated with single-gene testing, as only a simple blood draw is required for the simultaneous detection of 523 genes.

Ideal Treatment

Nominates proper targeted options, immunotherapy, chemotherapy, or hormonal therapy.

Smart Budgeting

Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting funds.

Learn More

How to Decide Which Treatment is Better for You?

The precision medicine approach can assist physicians and patients to confidently navigate the dynamic maze of cancer treatment being directed by genomic mutations, and a study has shown that precision medicine was able to double the percentage of cancer patients who achieved tumor shrinkage. The power of genomics should never be underestimated, as the information contained in the 523 genes associated with cancer has the power to change a patient's life dramatically, as they can identify the right immunotherapy, targeted therapy, chemotherapy, or hormonal therapy.

Diagnostic Solutions for All Cancers

Through next-generation sequencing (NGS), ACTLiquidTM Pro comprehensive genomic profiling decodes 523 cancer-related genes to map drug options based on thorough clinical research, rather than being limited to a single clinical treatment guideline. ACTLiquidTM Pro is able to determine the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.

Who Is Suitable for ACTLiquid™ Pro?

  • For pan solid tumors
  • Advanced, recurrent and metastatic cancer
  • Who are medically unfit or contraindicated for invasive tissue sampling


No items found.

Disclaimers / Footnotes

  1. Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.

Book a Test

Explore the immense possibilities and promising future of precision medicine. Together, let us unlock the power of genomic testing and personalize cancer care for the most effective treatment.

Get Started